MX370570B - Marcador para trastornos de la esfingomielinasa acida y sus usos. - Google Patents

Marcador para trastornos de la esfingomielinasa acida y sus usos.

Info

Publication number
MX370570B
MX370570B MX2015016844A MX2015016844A MX370570B MX 370570 B MX370570 B MX 370570B MX 2015016844 A MX2015016844 A MX 2015016844A MX 2015016844 A MX2015016844 A MX 2015016844A MX 370570 B MX370570 B MX 370570B
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
marker
disorders
asm
sphingomyelinase disorders
Prior art date
Application number
MX2015016844A
Other languages
English (en)
Other versions
MX2015016844A (es
Inventor
Lien Chuang Wei-
f cox Gerald
X Zhang Kate
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015016844A publication Critical patent/MX2015016844A/es
Publication of MX370570B publication Critical patent/MX370570B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere a métodos de evaluación, diagnóstico, control y/o tratamiento de trastornos de la esfingomielinasa ácida (ASM), tales como la enfermedad de Niemann-Pick. En particular, los métodos abarcan técnicas para diagnóstico y/o tratamiento mejorados de un trastorno de la ASM, por ejemplo usando terapia de sustitución de enzimas.
MX2015016844A 2013-06-07 2014-06-06 Marcador para trastornos de la esfingomielinasa acida y sus usos. MX370570B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016844A MX2015016844A (es) 2016-04-04
MX370570B true MX370570B (es) 2019-12-17

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016844A MX370570B (es) 2013-06-07 2014-06-06 Marcador para trastornos de la esfingomielinasa acida y sus usos.

Country Status (29)

Country Link
US (4) US10022428B2 (es)
EP (2) EP3004896B1 (es)
JP (4) JP6457501B2 (es)
KR (3) KR102292298B1 (es)
CN (2) CN105474017A (es)
AU (5) AU2014274670B2 (es)
CA (1) CA2914751C (es)
CL (1) CL2015003563A1 (es)
CR (1) CR20150638A (es)
DK (1) DK3004896T3 (es)
EA (1) EA035342B1 (es)
ES (1) ES2762608T3 (es)
HR (1) HRP20192246T1 (es)
HU (1) HUE047863T2 (es)
IL (3) IL284102B2 (es)
LT (1) LT3004896T (es)
MA (1) MA38638B1 (es)
MX (1) MX370570B (es)
MY (1) MY185990A (es)
NZ (1) NZ754328A (es)
PH (1) PH12015502687A1 (es)
PL (1) PL3004896T3 (es)
PT (1) PT3004896T (es)
RS (1) RS59677B1 (es)
SG (2) SG11201509622WA (es)
SI (1) SI3004896T1 (es)
UA (1) UA120591C2 (es)
WO (1) WO2014197859A1 (es)
ZA (1) ZA201508630B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5955219B2 (ja) * 2009-08-28 2016-07-20 アイカーン スクール オブ メディスン アット マウント シナイ 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
UA120591C2 (uk) * 2013-06-07 2020-01-10 Джензім Корпорейшн Спосіб контролю лікування дефіциту кислої сфінгомієлінази (asm) у пацієнта
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
ES2970423T3 (es) 2017-08-24 2024-05-28 Genzyme Corp Esfingomielinasa ácida humana recombinante para su uso en el tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida
EP3904389A1 (en) 2017-10-02 2021-11-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AU2020282831A1 (en) * 2019-05-31 2021-12-16 Genzyme Corporation Two-dimensional LC-MS/MS systems
EP4562432A2 (en) * 2022-07-28 2025-06-04 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
JP5955219B2 (ja) * 2009-08-28 2016-07-20 アイカーン スクール オブ メディスン アット マウント シナイ 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd ３次元測位システム
WO2013072060A2 (en) * 2011-11-15 2013-05-23 Centogene Gmbh Method for the diagnosis of niemann-pick disease
CA2912274A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
UA120591C2 (uk) * 2013-06-07 2020-01-10 Джензім Корпорейшн Спосіб контролю лікування дефіциту кислої сфінгомієлінази (asm) у пацієнта

Also Published As

Publication number Publication date
MA38638A1 (fr) 2017-02-28
PL3004896T3 (pl) 2020-04-30
JP2019089767A (ja) 2019-06-13
IL298675B2 (en) 2025-12-01
SG11201509622WA (en) 2015-12-30
US10022428B2 (en) 2018-07-17
US20180289778A1 (en) 2018-10-11
IL242964B (en) 2021-07-29
KR102228367B1 (ko) 2021-03-16
JP7414750B2 (ja) 2024-01-16
JP6457501B2 (ja) 2019-01-23
MA38638B1 (fr) 2018-03-30
CN105474017A (zh) 2016-04-06
ZA201508630B (en) 2020-01-29
HK1217534A1 (en) 2017-01-13
DK3004896T3 (da) 2020-01-06
PH12015502687A1 (en) 2016-03-07
AU2014274670B2 (en) 2017-11-09
US11998592B2 (en) 2024-06-04
AU2018200977B2 (en) 2020-07-23
AU2020257114A1 (en) 2020-11-19
AU2023201062B2 (en) 2025-05-29
KR20210031541A (ko) 2021-03-19
UA120591C2 (uk) 2020-01-10
HUE047863T2 (hu) 2020-05-28
WO2014197859A1 (en) 2014-12-11
KR20160018651A (ko) 2016-02-17
CL2015003563A1 (es) 2016-08-05
NZ754328A (en) 2021-12-24
RS59677B1 (sr) 2020-01-31
HRP20192246T1 (hr) 2020-03-06
KR102292298B1 (ko) 2021-08-24
AU2023201062A1 (en) 2023-03-23
LT3004896T (lt) 2020-01-10
BR112015030099A2 (pt) 2017-07-25
AU2025220876A1 (en) 2025-09-11
EP3004896B1 (en) 2019-09-18
US20160120958A1 (en) 2016-05-05
US20240398907A1 (en) 2024-12-05
AU2018200977A1 (en) 2018-03-01
EA035342B1 (ru) 2020-05-29
EP3004896A1 (en) 2016-04-13
IL284102B (en) 2022-12-01
CA2914751C (en) 2023-10-03
IL284102B2 (en) 2023-04-01
SG10201709925SA (en) 2017-12-28
NZ715001A (en) 2021-10-29
SI3004896T1 (sl) 2020-01-31
ES2762608T3 (es) 2020-05-25
AU2020257114B2 (en) 2023-03-16
JP2016526050A (ja) 2016-09-01
JP6835806B2 (ja) 2021-02-24
MX2015016844A (es) 2016-04-04
JP2024038145A (ja) 2024-03-19
US10888607B2 (en) 2021-01-12
JP2021075544A (ja) 2021-05-20
MY185990A (en) 2021-06-14
IL298675B1 (en) 2025-08-01
AU2014274670A1 (en) 2016-01-07
PT3004896T (pt) 2019-12-23
CA2914751A1 (en) 2014-12-11
EA201592265A1 (ru) 2016-04-29
KR102434244B1 (ko) 2022-08-19
US20210162021A1 (en) 2021-06-03
IL284102A (en) 2021-07-29
CR20150638A (es) 2016-02-08
KR20210104177A (ko) 2021-08-24
CN115128287A (zh) 2022-09-30
IL298675A (en) 2023-01-01
EP3584580A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
PH12017502153A1 (en) Diagnostic methods for t cell therapy
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
NZ720949A (en) Methods and compositions for treating aging-associated conditions
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
FI20145492A7 (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2014009143A (es) Metodos y sistemas para evaluar la actividad muscular electrica en respuesta a la estimulacion de un nervio motor.
AU2014212471A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
WO2013090633A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
MX2015015907A (es) Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
WO2015085314A3 (en) Methods for detection of heart failure
MY194135A (en) Treatment and diagnosis of inflammatory disorders
EP3044321A4 (en) New marker for the classification, diagnosis and treatment of scoliosis
WO2014126796A3 (en) Methods of diagnosing, treating and monitoring diabetic retinopathy
GB201105129D0 (en) Compositions and methods for treating, diagnosing and monitoring disease

Legal Events

Date Code Title Description
FG Grant or registration